ICP-248 is named as an intervention in 5 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Beijing InnoCare Pharma Tech Co., Ltd. The most-studied condition is Relapsed or Refractory Mantle Cell Lymphoma (MCL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138 · ClinicalTrials.gov ↗ · Hematologic Malignancies
|
Phase 2/3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | China |
|
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
NCT07082686 · ClinicalTrials.gov ↗ · Relapsed or Refractory Mantle Cell Lymphoma (MCL)
|
Phase 2 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | China |
|
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658 · ClinicalTrials.gov ↗ · Hematological Malignancies
|
Phase 1 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | China |
|
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494 · ClinicalTrials.gov ↗ · Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
|
Phase 1 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | USA, China |
|
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
NCT07784101 · ClinicalTrials.gov ↗ · Relapsed or Refractory Mantle Cell Lymphoma (MCL)
|
Phase 3 | Not yet open | Beijing InnoCare Pharma Tech Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Beijing InnoCare Pharma Tech Co., Ltd. | 5 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China and USA registers name ICP-248 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 4 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Beijing InnoCare Pharma Tech Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ICP-248 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ICP-248 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ICP-248 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.